{"id":"hydromorphone-hydrochloride-extended-release-tablets","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Headache"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydromorphone is a potent mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain and spinal cord to modulate pain perception and transmission. The extended-release formulation provides sustained drug delivery over an extended period, allowing for less frequent dosing in chronic pain management. It is approximately 6-7 times more potent than morphine on a milligram-for-milligram basis.","oneSentence":"Hydromorphone hydrochloride is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:06.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic moderate to severe pain requiring around-the-clock opioid therapy"}]},"trialDetails":[{"nctId":"NCT07489625","phase":"EARLY_PHASE1","title":"Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Qinghai Red Cross Hospital","startDate":"2026-03-07","conditions":"Refractory Cancer Pain, Cancer Pain","enrollment":30},{"nctId":"NCT04044820","phase":"NA","title":"Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-03-04","conditions":"Opioid Use","enrollment":292},{"nctId":"NCT04018664","phase":"PHASE1","title":"Oral Abuse Potential Study of Nalbuphine","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2018-05-29","conditions":"Nalbuphine, Opioid Abuse","enrollment":56},{"nctId":"NCT04033094","phase":"","title":"Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-10-16","conditions":"Baseline Epidemiologic Assessment","enrollment":17566},{"nctId":"NCT02321319","phase":"PHASE3","title":"Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2017-03-11","conditions":"Chronic Pain","enrollment":5},{"nctId":"NCT04132011","phase":"PHASE4","title":"Dosing Intervals of Opioid Medication for Chronic Pain","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT02987920","phase":"PHASE4","title":"Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-01","conditions":"Pain, Postoperative","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Exalgo, Jurnista"],"phase":"phase_3","status":"active","brandName":"Hydromorphone Hydrochloride Extended-Release Tablets","genericName":"Hydromorphone Hydrochloride Extended-Release Tablets","companyName":"Qinghai Red Cross Hospital","companyId":"qinghai-red-cross-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydromorphone hydrochloride is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Chronic moderate to severe pain requiring around-the-clock opioid therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}